Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Malaria vaccine live attenuated - Sanaria

Drug Profile

Malaria vaccine live attenuated - Sanaria

Alternative Names: Pf delta b9 delta Slarp; PfSPZ malaria vaccine live attenuated - Sanaria; PfSPZ Vaccine - Sanaria; PfSPZ-GA1; Pf∆b9∆Slarp; Plasmodium falciparum sporozoite vaccine live attenuated - Sanaria; Sanaria PfSPZ Vaccine

Latest Information Update: 24 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sanaria
  • Developer National Institute of Allergy and Infectious Diseases; PATH; Sanaria
  • Class Attenuated vaccines; Malaria vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Falciparum malaria

Most Recent Events

  • 18 Jun 2019 Phase-II clinical trials in Falciparum malaria (Prevention) in Mali (IV) (NCT03989102)
  • 10 Apr 2019 Sanaria and the Government of the Republic of Guinea expand the agreement with oil and gas sector partners for sponsoring the clinical development of malaria vaccine live attenuated
  • 10 Apr 2019 Sanaria announces intention to submit regulatory submissions to the US FDA and the EMA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top